Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China
Article in International Journal of Clinical Pharmacy (May 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis
Article in PLOS ONE (October 2023)
Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China
Article in BMJ Open (September 2023)